TRVI Stock Forecast & Price Target

Trevi Therapeutics is well-positioned to succeed in the competitive biopharmaceutical market, with its promising investigational therapy Haduvio showing significant benefits in reducing cough frequency and improving quality of life for patients with chronic cough in multiple indications, including IPF and RCC. This is supported by strong clinical results from the CORAL and RIVER trials and a recent equity raise extending cash runway into 2030, mitigating any financing concerns. However, there are potential risks such as reimbursement uncertainty and regulatory and trial risks that may impact Trevi's success in gaining approval for Haduvio. Overall, we believe the current valuation does not fully reflect Haduvio's potential across multiple chronic cough indications, and expect clinical execution to continue to support upside to Trevi's stock.

Trevi Therapeutics is facing regulatory risks as they plan to get approval for their investigational therapy, Haduvio, through the abbreviated 505(b)(2) pathway and the path to approval for its use in IPF cough, RCC, and PN still needs clarification from regulators. Additionally, competition from upcoming P2X3 antagonist therapies may also negatively impact Trevi's market position. Furthermore, the potential off-label usage of Haduvio in RCC and non-IPF ILD may not provide enough incremental revenue to compensate for the lack of approved therapies in chronic cough populations. From a financial perspective, Trevi's financials are quite concerning as they have a negative operating income of $-40.19 million and a negative gross profit of $-5,000. Additionally, their total assets have decreased from $46.5 million in 2019 to $25 million in 2020, showing a decrease in their financial stability. This, combined with the regulatory uncertainties and potential competition in the market, paints a negative outlook on the stock of Trevi Therapeutics.